EUVIMEDEUVIMED entdecken
Crossref

Design and Evaluation of Compritol–Oleic Acid Nanostructured Lipid Carriers: A New Approach to Type 2 Diabetes Therapy

Adnan Nadir, Saifullah Afridi iD, Umar Nishan, Shen Lv, İhsan Boyaci, Fawad Muhammad, Zakir Ullah, Muhammad Junaid, Abeer Tariq, Hamid Khan, Muhammad Usman, Aqeedat Javed und 4 weitere

The FASEB Journal · 15.11.2026 · 40 (21)

DOI: 10.1096/fj.202603856r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 30.10.2026. Verfasst von Adnan Nadir und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Care Technology, Faculty of Allied Health Sciences, Kohat University of Science and Technology, Kohat, Pakistan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Oleic Acid, Diabetes Mellitus, Experimental, Drug Carriers. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China-Guangdong Joint Fund, KKU|Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder caused by reduced insulin production and sensitivity. Despite advancements in antidiabetic medications, many patients struggle with poor glycemic control. Combining drugs like sitagliptin (STG) and glipizide (GPZ) can improve treatment efficacy, but their low solubility and rapid excretion limit their effectiveness. To address these challenges, this study developed novel compritol and oleic acid‐based nanostructured lipid carriers (NLCs) for the co‐delivery of STG and GPZ. The NLCs were prepared using a modified microemulsion technique and optimized using the Box–Behnken model, focusing on particle size, zeta potential, and entrapment efficiency. The optimized NLCs exhibited a particle size of 275.5 nm, zeta potential of −23.4 mV, PDI of 0.134, and high entrapment efficiencies of 88% for STG and 85% for GPZ. Characterization was performed using FTIR, XRD, DSC, and TEM techniques. In vitro release studies at pH 1.2, 6.8, and 7.4 demonstrated prolonged drug release from the NLCs compared to pure drug solutions. In vivo studies in a nicotinamide‐streptozotocin‐induced diabetic rat model revealed that STG‐GPZ co‐loaded NLCs (10/2.5 mg/kg/b.w.) significantly improved pancreatic and liver function histology and exhibited synergistic antihyperglycemic effects. Statistical analysis confirmed the significance of these findings, highlighting the potential of STG‐GPZ co‐loaded NLCs as an effective oral drug delivery system for T2DM treatment and management. This innovative approach offers a promising solution to enhance therapeutic outcomes for diabetic patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Oleic AcidDiabetes Mellitus, ExperimentalDrug CarriersNanostructuresHypoglycemic AgentsLipidsFatty AcidsAnimalsRatsMaleParticle SizeRats, Sprague-DawleyGlipizideDrug LiberationBlood GlucoseRats, Wistar

Stichwörter der Autor:innen

antidiabeticcompritol‐oleic acidnanostructured lipid carriersitagliptin‐glipizidetype 2 diabetes

Substanzen

Oleic AcidDrug CarriersHypoglycemic AgentsLipidsglyceryl behenateFatty AcidsGlipizideBlood Glucose

Autor:innen und Institutionen

  • Department of Emergency Care Technology, Faculty of Allied Health Sciences, Kohat University of Science and Technology, Kohat, Pakistan.
  • Department of Internal Medicine, Faculty of Medicine, İstanbul Medipol University, İstanbul, Türkiye.
  • Molecular Oncology Laboratory, Vaccine and Drug Development Biotechnology Research Group, VPCLS, TUBİTAK Marmara Research Center, Istanbul, Kocaeli, Turkey.
  • Department of Chemistry, Kohat University of Science and Technology, Kohat, Pakistan.
  • Department of Pediatrics, Longgang Maternity and Child Institute of Shantou University Medical College (Longgang District Maternity & Child Healthcare Hospital of Shenzhen City), Shenzhen, China.
  • Department of Microbiology &Molecular Biology, Peshawar Medical College, Peshawar, Khyber Pakhtunkhwa, Pakistan.

ORCID-Profile: Saifullah Afridi

Förderung

  • National Natural Science Foundation of China-Guangdong Joint Fund
  • KKU|Deanship of Scientific Research, King Khalid University

Zitieren

APA

Nadir, A., Afridi, S., Nishan, U., Lv, S., Boyaci, İ., Muhammad, F., Ullah, Z., Junaid, M., Tariq, A., Khan, H., Usman, M., Javed, A., Rahman, A. A., Anwar, K., Fawy, K. F., & Khan, A. (2026). Design and Evaluation of Compritol–Oleic Acid Nanostructured Lipid Carriers: A New Approach to Type 2 Diabetes Therapy. The FASEB Journal, 40(21). https://doi.org/10.1096/fj.202603856r

Vancouver

Nadir A, Afridi S, Nishan U, Lv S, Boyaci İ, Muhammad F, et al. Design and Evaluation of Compritol–Oleic Acid Nanostructured Lipid Carriers: A New Approach to Type 2 Diabetes Therapy. The FASEB Journal. 2026;40(21). doi:10.1096/fj.202603856r

BibTeX
@article{Nadir2026,
  author = {Nadir, Adnan and Afridi, Saifullah and Nishan, Umar and Lv, Shen and Boyaci, İhsan and Muhammad, Fawad and Ullah, Zakir and Junaid, Muhammad and Tariq, Abeer and Khan, Hamid and Usman, Muhammad and Javed, Aqeedat and Rahman, Ahmad Abdur and Anwar, Khurshid and Fawy, Khaled Fahmi and Khan, Ahmad},
  title = {Design and Evaluation of Compritol–Oleic Acid Nanostructured Lipid Carriers: A New Approach to Type 2 Diabetes Therapy},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {21},
  doi = {10.1096/fj.202603856r}
}
Kostenlos starten →